Literature DB >> 12959222

Immunoglobulin deficiencies and susceptibility to infection among homozygotes and heterozygotes for C2 deficiency.

Chester A Alper1, Jianhua Xu, Katherine Cosmopoulos, Brian Dolinski, Rosanne Stein, Gabriel Uko, Charles E Larsen, Devendra P Dubey, Peter Densen, Lennart Truedsson, Gunnar Sturfelt, Anders G Sjöholm.   

Abstract

About 25% of C2-deficient homozygotes have increased susceptibility to severe bacterial infections. C2-deficient homozygotes had significantly lower serum levels of IgG2, IgG4, IgD, and Factor B, significantly higher levels of IgA and IgG3 and levels of IgG1 and IgM similar to controls. Type 1 (28 bp deletion in C2 exon 6 on the [HLA-B18, S042, DR2] haplotype or its fragments) and type II (non-type I) C2-deficient patients with increased susceptibility to bacterial infection had significantly lower mean levels of IgG4 (p < 0.04) and IgA (p < 0.01) than those without infections (who had a higher than normal mean IgA level) but similar mean levels of other immunoglobulins and Factor B. Of 13 C2-deficient homozygotes with infections, 85% had IgG4 deficiency, compared with 64% of 25 without infections. IgD deficiency was equally extraordinarily common among infection-prone (50%) and noninfection-prone (70%) homozygous type I C2-deficient patients. IgD deficiency was also common (35%) among 31 type I C2-deficient heterozygotes (with normal or type II haplotypes), but was not found in 5 type II C2-deficient heterozygotes or 1 homozygote. Thus, C2 deficiency itself is associated with many abnormalities in serum immunoglobulin levels, some of which, such as in IgG4 and IgA, may contribute to increased susceptibility to infection. In contrast, IgD deficiency appears not to contribute to increased infections and appears to be a dominant trait determined by a gene or genes on the extended major histocompatibility complex (MHC) haplotype [HLA-B 18, S042, DR2] (but probably not on type II C2-deficient haplotypes) similar to those previously identified on [HLA-B8, SC01, DR3] and [HLA-B18, F1C30, DR3].

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12959222     DOI: 10.1023/a:1024540917593

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  41 in total

1.  Vaccination responses to capsular polysaccharides of Neisseria meningitidis and Haemophilus influenzae type b in two C2-deficient sisters: alternative pathway-mediated bacterial killing and evidence for a novel type of blocking IgG.

Authors:  B Selander; H Käyhty; E Wedege; E Holmström; L Truedsson; C Söderström; A G Sjöholm
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

Review 2.  IgA deficiency.

Authors:  P D Burrows; M D Cooper
Journal:  Adv Immunol       Date:  1997       Impact factor: 3.543

Review 3.  The role of complement and complement receptors in induction and regulation of immunity.

Authors:  M C Carroll
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

4.  Hereditary deficiency of the second component of complement (C'2) in man.

Authors:  M R Klemperer; H C Woodworth; F S Rosen; K F Austen
Journal:  J Clin Invest       Date:  1966-06       Impact factor: 14.808

5.  Automated quantitation of proteins in serum and other biologic fluids.

Authors:  R F Ritchie; C A Alper; J Graves; N Pearson; C Larson
Journal:  Am J Clin Pathol       Date:  1973-02       Impact factor: 2.493

6.  Type II human complement C2 deficiency. Allele-specific amino acid substitutions (Ser189 --> Phe; Gly444 --> Arg) cause impaired C2 secretion.

Authors:  R A Wetsel; J Kulics; M L Lokki; P Kiepiela; H Akama; C A Johnson; P Densen; H R Colten
Journal:  J Biol Chem       Date:  1996-03-08       Impact factor: 5.157

7.  Low concentrations of immunoglobulin G antibodies to Salmonella serogroup C in C2 deficiency: suggestion of a mannan-binding lectin pathway-dependent mechanism.

Authors:  B Selander; A Weintraub; E Holmström; G Sturfelt; L Truedsson; U Mårtensson; J C Jensenius; A G Sjöholm
Journal:  Scand J Immunol       Date:  1999-12       Impact factor: 3.487

8.  Recurrent sinopulmonary infection and impaired antibody response to bacterial capsular polysaccharide antigen in children with selective IgG-subclass deficiency.

Authors:  D T Umetsu; D M Ambrosino; I Quinti; G R Siber; R S Geha
Journal:  N Engl J Med       Date:  1985-11-14       Impact factor: 91.245

9.  Complement-human histocompatibility antigen haplotypes in C2 deficiency.

Authors:  Z L Awdeh; D D Raum; D Glass; V Agnello; P H Schur; R B Johnston; E W Gelfand; M Ballow; E Yunis; C A Alper
Journal:  J Clin Invest       Date:  1981-02       Impact factor: 14.808

10.  Characterization of type I complement C2 deficiency MHC haplotypes. Strong conservation of the complotype/HLA-B-region and absence of disease association due to linked class II genes.

Authors:  L Truedsson; C A Alper; Z L Awdeh; P Johansen; A G Sjöholm; G Sturfelt
Journal:  J Immunol       Date:  1993-11-15       Impact factor: 5.422

View more
  9 in total

1.  Incomplete penetrance of susceptibility genes for MHC-determined immunoglobulin deficiencies in monozygotic twins discordant for type 1 diabetes.

Authors:  Chester A Alper; Zaheed Husain; Charles E Larsen; Devendra P Dubey; Rosanne Stein; Caitlin Day; Alissa Baker; Huriya Beyan; Mohammed Hawa; Thomas O Ola; R David Leslie
Journal:  J Autoimmun       Date:  2006-10-06       Impact factor: 7.094

2.  Immunoglobulins and complement factor C4 in adult rhinosinusitis.

Authors:  M Seppänen; J Suvilehto; M-L Lokki; I-L Notkola; A Järvinen; H Jarva; I Seppälä; O Tahkokallio; H Malmberg; S Meri; V Valtonen
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

Review 3.  Infections of people with complement deficiencies and patients who have undergone splenectomy.

Authors:  Sanjay Ram; Lisa A Lewis; Peter A Rice
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

Review 4.  Immune responses in neonates.

Authors:  Saleem Basha; Naveen Surendran; Michael Pichichero
Journal:  Expert Rev Clin Immunol       Date:  2014-08-04       Impact factor: 4.473

5.  Role of complement in host defense against pneumococcal otitis media.

Authors:  Vishakha Sabharwal; Sanjay Ram; Marisol Figueira; In Ho Park; Stephen I Pelton
Journal:  Infect Immun       Date:  2009-01-12       Impact factor: 3.441

6.  Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration.

Authors:  Bert Gold; Joanna E Merriam; Jana Zernant; Lisa S Hancox; Andrew J Taiber; Karen Gehrs; Kevin Cramer; Julia Neel; Julie Bergeron; Gaetano R Barile; R Theodore Smith; Gregory S Hageman; Michael Dean; Rando Allikmets
Journal:  Nat Genet       Date:  2006-03-05       Impact factor: 38.330

7.  Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases.

Authors:  Paolo G V Martini; Lynette C Cook; Scott Alderucci; Angela W Norton; Dianna M Lundberg; Susan M Fish; Knut Langsetmo; Göran Jönsson; Christian Lood; Birgitta Gullstrand; Kate J Zaleski; Nancy Savioli; Jason Lottherand; Charles Bedard; John Gill; Michael F Concino; Michael W Heartlein; Lennart Truedsson; Jan L Powell; Arthur O Tzianabos
Journal:  BMC Immunol       Date:  2010-08-20       Impact factor: 3.615

8.  Hereditary Deficiency of the Second Component of Complement: Early Diagnosis and 21-Year Follow-Up of a Family.

Authors:  Rosa Maria Dellepiane; Lucia Augusta Baselli; Marco Cazzaniga; Vassilios Lougaris; Paolo Macor; Mara Giordano; Roberta Gualtierotti; Massimo Cugno
Journal:  Medicina (Kaunas)       Date:  2020-03-10       Impact factor: 2.430

9.  Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens.

Authors:  Benjamin J Read; Lori Won; John C Kraft; Isaac Sappington; Aereas Aung; Shengwei Wu; Julia Bals; Chengbo Chen; Kelly K Lee; Daniel Lingwood; Neil P King; Darrell J Irvine
Journal:  Cell Rep       Date:  2022-01-11       Impact factor: 9.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.